Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VT-EBV-N
- Development stage
- Phase 2
- Lead developer
- ViGenCell
- Modality
- Vaccines & Immunotherapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
VT-EBV-N is an investigational immunotherapy developed by ViGenCell for the treatment of Epstein-Barr Virus (EBV)-positive extranodal NK/T cell lymphoma, a rare and aggressive form of blood cancer. The therapy consists of autologous EBV-specific cytotoxic T lymphocytes (CTLs), designed to target and eliminate EBV-infected malignant cells. VT-EBV-N has been designated as an orphan drug in Europe and is currently in phase 2 clinical trials, with promising early results showing high overall survival and progression-free survival rates in patients with relapsed or refractory disease[1][2][3]. The primary mechanism involves adoptive transfer of T lymphocytes that specifically recognize EBV antigens presented on tumor cells, thereby enhancing immune-mediated clearance.
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on VT-EBV-N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VT-EBV-N.